Key Points
- SVP Lauren Riker sold 4,000 Pacira shares on Feb. 2 at $20.81 each for $83,240, cutting her holdings by 7.10% to 52,313 shares worth roughly $1.09M.
- Pacira stock opened at $21.02, trading below its 50‑day ($23.68) and 200‑day ($23.93) moving averages, with a 12‑month range of $18.80–$27.64 and a market cap of about $904M.
- The company beat quarterly EPS estimates but missed revenue expectations; analysts have mixed views and the consensus rating is a Hold with a $30.75 price target.
Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) SVP Lauren Riker sold 4,000 shares of the business's stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $20.81, for a total transaction of $83,240.00. Following the transaction, the senior vice president owned 52,313 shares in the company, valued at approximately $1,088,633.53. This trade represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Lauren Riker also recently made the following trade(s):
- On Monday, January 5th, Lauren Riker sold 1,416 shares of Pacira BioSciences stock. The shares were sold at an average price of $24.24, for a total value of $34,323.84.
Pacira BioSciences Stock Performance
Shares of Pacira BioSciences stock opened at $21.02 on Wednesday. The business's fifty day simple moving average is $23.68 and its 200 day simple moving average is $23.93. The company has a current ratio of 5.26, a quick ratio of 3.78 and a debt-to-equity ratio of 0.52. Pacira BioSciences, Inc. has a 12 month low of $18.80 and a 12 month high of $27.64. The firm has a market capitalization of $904.28 million, a P/E ratio of 46.71 and a beta of 0.24.
Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. The company had revenue of $179.52 million during the quarter, compared to analyst estimates of $182.86 million. Pacira BioSciences had a net margin of 2.99% and a return on equity of 12.82%. The firm's revenue for the quarter was up 6.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.79 earnings per share. As a group, analysts anticipate that Pacira BioSciences, Inc. will post 2.41 EPS for the current year.
Hedge Funds Weigh In On Pacira BioSciences
Hedge funds have recently bought and sold shares of the company. Hantz Financial Services Inc. increased its holdings in Pacira BioSciences by 175.4% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company's stock worth $29,000 after acquiring an additional 721 shares during the period. Tidemark LLC purchased a new position in shares of Pacira BioSciences during the 3rd quarter valued at $56,000. Strs Ohio bought a new position in shares of Pacira BioSciences in the first quarter worth $75,000. Wolverine Asset Management LLC raised its position in shares of Pacira BioSciences by 122.1% in the fourth quarter. Wolverine Asset Management LLC now owns 3,000 shares of the company's stock worth $78,000 after buying an additional 16,572 shares in the last quarter. Finally, iSAM Funds UK Ltd bought a new stake in Pacira BioSciences during the third quarter valued at $80,000. Hedge funds and other institutional investors own 99.73% of the company's stock.
Wall Street Analysts Forecast Growth
PCRX has been the topic of a number of research reports. HC Wainwright reaffirmed a "buy" rating and issued a $38.00 price target on shares of Pacira BioSciences in a report on Friday, January 9th. Wall Street Zen upgraded Pacira BioSciences from a "buy" rating to a "strong-buy" rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Pacira BioSciences in a research note on Monday, December 29th. Truist Financial lowered their price objective on Pacira BioSciences from $30.00 to $28.00 and set a "buy" rating on the stock in a research note on Friday, November 7th. Finally, Barclays started coverage on shares of Pacira BioSciences in a report on Tuesday, December 9th. They set an "equal weight" rating and a $27.00 price objective on the stock. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $30.75.
Check Out Our Latest Analysis on PCRX
Pacira BioSciences Company Profile
(
Get Free Report)
Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company's flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.
In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
